ACM  >> Vol. 5 No. 4 (December 2015)

    miR-183在不同分期胃癌中的表达及意义
    The Expression and Clinical Significance of miR-183 in Gastric Cancer of Different Tumor Stages

  • 全文下载: PDF(468KB) HTML   XML   PP.219-224   DOI: 10.12677/ACM.2015.54035  
  • 下载量: 619  浏览量: 3,699  

作者:  

顾 玮,胡梅洁,胡晓莹,孙 颖,马 瑾:上海交通大学医学院附属瑞金医院卢湾分院消化内科,上海

关键词:
微小RNAmiR-183胃癌TNM分期micro-RNA miR-183 Gastric Cancer TNM Stage

摘要:

目的:检测miR-183在不同分期胃癌中的表达量并讨论其临床意义。方法:实时定量PCR(real-time PCR,RT-PCR)法检测100例胃癌组织与其中20例相应癌旁组织中miR-183的表达水平,分析miR-183表达水平与胃癌患者临床病理特征及预后的关系。结果:胃癌组织中miR-183表达量明显高于相对应癌旁正常组织(2.12 ± 0.24比1.04 ± 0.15,p < 0.01) miRNA-183表达水平与临床病理肿瘤MTN分型,淋巴结转移,远处转移及肿瘤浸润程度有关(p < 0.05),与性别、年龄、肿瘤大小、分化程度无关(p > 0.05)。ROC曲线分析显示,miR-183在预测肿瘤转移时,其AUC值为0.74 (95% CI为0.530~0.865),敏感度为50.0%,特异性为90.0%;结论:miR-183在胃癌组织中的表达上调与胃癌的临床病理特征及患者预后密切相关,miR-183可能成为胃癌诊断及预后判断的新的分子标志。

Objective: To quantitate expression of miR-183 in gastric cancer of different tumor stages and discuss their significances. Methods: Real-time PCR was used to detect the miR-183 expressions between gastric cancer tissues and matched adjacent tissues. The correlations of miR-183 expres-sion with clinic-pathological features and clinical prognosis were analyzed. Results: The significant overexpression of miR-183 was observed in the rectal cancer tissues (2.12 ± 0.24 versus 1.04 ± 0.15, p < 0.01) as compared with the corresponding adjacent normal tissues. Up-regulation of miR-183 is associated with advanced clinical stage, positive lymph node, deep stromal invasion, and distant metastasis in gastric cancer patients. Conclusion: The expression of miR-183 is associated with clinic-pathological features and patient’s clinical prognosis, so it may be used as a potential diagnostic biomarker and a prognostic predictor in patients with gastric cancer.

文章引用:
顾玮, 胡梅洁, 胡晓莹, 孙颖, 马瑾. miR-183在不同分期胃癌中的表达及意义[J]. 临床医学进展, 2015, 5(4): 219-224. http://dx.doi.org/10.12677/ACM.2015.54035

参考文献

[1] Varadhachary, G. and Ajani, J.A. (2005) Gastric Cancer. Clinical Advances in Hematology & Oncology, 3, 118-124.
[2] Parkin, D.M., Bray, F., Ferlay, J., et al. (2005) Global Cancer Statistics, 2002. CA: A Cancer Journal for Clinicians, 55, 74-108.
http://dx.doi.org/10.3322/canjclin.55.2.74
[3] 孙秀娣, 牧人, 周有尚, 等. 中国胃癌死亡率20年变化情况分析及其发展趋势预测[J]. 中华肿瘤学杂志, 2004, 26(1): 4-9.
[4] Wu, W., Sun, M., Zou, G.M., et al. (2007) Micro RNA and Cancer: Current Status and Prospective. International Jour- nal of Cancer, 120, 953-960.
http://dx.doi.org/10.1002/ijc.22454
[5] Baranwal, S. and Alahari, S.K. (2010) miRNA Control of Tumor Cell in Vasion and Metastasis. International Journal of Cancer, 126, 1283-1290.
[6] Bartel, D.P. (2009) MicroRNAs: Target Recognition and Regulatory Functions. Cell, 136, 215-233.
http://dx.doi.org/10.1016/j.cell.2009.01.002
[7] Bartels, D.P. and Tsongalis, G.J. (2009) MicroRNAs: Novel Biomarkers for Human Cancer. Clinical Chemistry, 55, 623-631.
http://dx.doi.org/10.1373/clinchem.2008.112805
[8] 顾玮, 胡梅洁, 孙颖, 等. 胃癌外周血微小核糖核酸表达谱的初步分析[J]. 中华消化杂志, 2012, 32(4): 222-225.
[9] Ladeiro, Y., Couchy, G., Balabaud, G., et al. (2008) MicroRNA Profiling in Hepatocellular Tumors Is Associated with Clinical Features and Oncogene/Tumor Suppressor Gene Mutations. Hepatology, 47, 1955-1963.
http://dx.doi.org/10.1002/hep.22256
[10] Wang, G., Mao, W. and Zheng, S. (2008) MicroRNA-183 Regulates Ezrin Expression in Lung Cancer Cells. FEBS Letters, 582, 3663-3668.
http://dx.doi.org/10.1016/j.febslet.2008.09.051
[11] Davoren, P.A., McNeill, R.E., Lowery, A.J., Kerin, M.J. and Miller, N. (2008) Identification of Suitable Endogenous Control Genes for microRNA Gene Expression Analysis in Human Breast Cancer. BMC Molecular Biology, 9, 76.
http://dx.doi.org/10.1186/1471-2199-9-76
[12] Livak, K.J. and Schmittgen, T.D. (2001) Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods, 25, 402-408.
http://dx.doi.org/10.1006/meth.2001.1262
[13] Shibuya, H., Iinuma, H., Shimada, R., Horiuchi, A. and Watanabe, T. (2010) Clinicopathological and Prognostic Value of microRNA-21 and microRNA-155 in Colorectal Cancer. Oncology, 79, 313-320.
http://dx.doi.org/10.1159/000323283
[14] Corcoran, C., Rani, S., Breslin, S., et al. (2014) miR-630 Targets IGF1R to Regulate Response to HER-Targeting Drugs and Overall Cancer Cell Progression in HER2 Over-Expressing Breast Cancer. Molecular Cancer, 13, 71-81.
http://dx.doi.org/10.1186/1476-4598-13-71
[15] Jung, H.S., Seo, Y.R., Yang, Y.M., et al. (2014) Gα12 Gep On-cogene Inhibits FOXO1 in Hepatocellular Carcinoma as a Consequence of miR-135b and miR-194 Dysregulation. Cell Signalling, 26, 1456-1465.
http://dx.doi.org/10.1016/j.cellsig.2014.02.022
[16] Yang, T.S., Yang, X.H., Wang, X.D., et al. (2013) MiR-214 Regulate Gastric Cancer Cell Proliferation, Migration and Invasion by Targeting PTEN. Cancer Cell International, 13, 68-78.
http://dx.doi.org/10.1186/1475-2867-13-68
[17] Wang, P., Chen, L., Zhang, J., et al. (2014) Methyla-tion-Mediated Silencing of the miR-124 Genes Facilitates Pancreatic Cancer Progression and Metastasis by Targeting Rac1. Oncogene, 33, 514-524.
http://dx.doi.org/10.1038/onc.2012.598
[18] Shang, J., Yang, F., Wang, Y., et al. (2014) Micro RNA-23a Antisense Enhances 5-Fluorouracil Chemosensitivity through APAF-1/Caspase-9 Apoptotic Pathway in Colorectal Cancer Cells. Journal of Cellular Biochemistry, 115, 772-784.
http://dx.doi.org/10.1002/jcb.24721
[19] Gyugos, M., Lenvai, G., Kenessey, I., et al. (2014) Micro RNA Expres-sion Might Predict Prognosis of Epithelial Hepatoblastoma. Virchows Archiv, 464, 419-427.
http://dx.doi.org/10.1007/s00428-014-1549-y
[20] Piva, R., Spandidos, D.A. and Gambambari, R. (2013) From Micro RNA Functions to Micro RNA Therapeutics: Novel Targets and Novel Drugs in Breast Cancer Research and Treatment (Review). International Journal of Oncology, 43, 985-994.
[21] Li, J., Fu, H., Xu, C., et al. (2010) miR-NA-183 Inhibits TGF-Beta 1 Induced Apoptosis by Downregulation of PDCD4 Expression in Human Hepatocellular Carcinoma Cells. BMC Cancer, 10, 354.
http://dx.doi.org/10.1186/1471-2407-10-354.